Open AccessRandomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m2 versus 40 mg/m2 in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial
Author(s) -
T. Mutoh,
Akira Yabuno,
Hiroshi Michimae,
Tetsuro Ohishi,
Miwa aka,
Masashi Takano,
Shin Nishio,
Hiroyuki Fujiwara,
Keiichi Fujiwara,
Eiji Kondo,
Toru Sugiyama,
Tsutomu Tabata
Publication year - 2021
Publication title -
journal of gynecologic oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.358
H-Index - 37
eISSN - 2005-0399
pISSN - 2005-0380
DOI - 10.3802/jgo.2021.32.e9
Subject(s) - medicine , hazard ratio , tolerability , mucositis , clinical endpoint , toxicity , progression free survival , confidence interval , gastroenterology , randomized controlled trial , surgery , chemotherapy , urology , adverse effect